Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies
Cancer Chemotherapy and Pharmacology1988Vol. 22(3), pp. 256–262
Citations Over Time
M Gaspard, D Maraninchi, Anne Marie Stoppa, J.A. Gastaut, Gérard Michel, N. Tubiana-Mathieu, Didier Blaise, G Novakovitch, Jean François Rossi, P.J. Weiller, D Sainty, N. Horchowski, Y Carcassonne
Related Papers
- → High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma(2015)22 cited
- → Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation(2018)14 cited
- → A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)(2002)14 cited
- → High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease(1992)14 cited
- → A Comparison between BEAM and BEM Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Relapsed Lymphoma: A Retrospective Analysis(2019)